EMA Authorised: Jylamvo (methotrexate) — Oresund Pharma ApS

View source ↗

Summary

The European Medicines Agency authorised Jylamvo, a methotrexate product from Oresund Pharma ApS, for indications including psoriatic arthritis, rheumatoid arth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor B-cell Acute Lymphoblastic Leukemia Lymphoma
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• JYLAMVO (METHOTREXATE)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Psoriasis;Arthritis, Rheumatoid;Arthritis. MAH: Oresund Pharma ApS. Decision date: 21/10/2024